4//SEC Filing
Sendek Joel 4
Accession 0000899243-17-025507
CIK 0001701108other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 4:05 PM ET
Size
9.4 KB
Accession
0000899243-17-025507
Insider Transaction Report
Form 4
Sendek Joel
Chief Financial Officer
Transactions
- Purchase
Common Stock
2017-11-06$14.00/sh+5,000$70,000→ 15,181 total - Conversion
Common Stock
2017-11-06+10,181→ 10,181 total(indirect: By Trust) - Conversion
Series C Preferred Stock
2017-11-06−61,880→ 0 total(indirect: By Trust)→ Common Stock (10,181 underlying)
Footnotes (2)
- [F1]Amount of underlying securities reflects the application of the applicable conversion ratio as set forth in the Issuer's Amended and Restated Certificate of Incorporation in effect immediately prior to the closing of the initial public offering (as adjusted by the 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017). The preferred stock had no expiration date.
- [F2]Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
Related Parties
1- filerCIK 0001720875
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 4:05 PM ET
- Size
- 9.4 KB